Poor
Not Aligned
Patient Risk:
Medium
Summary
Several interaction-related claims are either unsupported or potentially incorrect relative to the provided label excerpts, which specifically discuss atorvastatin concentration increases with CYP3A4 inhibitors and do not describe warfarin-specific effects (INR changes, bleeding most common, or increased stroke/heart failure risk) in the supplied sections.
Category Scores
Accurate Statements
Unsupported Statements
Lipitor (atorvastatin) can increase the risk of bleeding when taken with warfarin.
The provided label excerpts do not mention warfarin or bleeding risk associated with concomitant warfarin use.
Lipitor can increase warfarin levels in the blood.
The provided label excerpts do not mention warfarin pharmacokinetics or warfarin level increases.
Taking Lipitor and warfarin together can increase the risk of bleeding compared with taking warfarin alone.
No warfarin interaction or comparative bleeding-risk statement is present in the provided excerpts.
Monitoring INR levels more frequently may be needed when taking Lipitor and warfarin together.
The provided label excerpts do not mention INR or INR monitoring guidance for warfarin coadministration.
Warfarin dose adjustment may be needed to minimize the risk of bleeding when taken with Lipitor.
No warfarin dose adjustment guidance appears in the provided label excerpts.
Bleeding is described as the most common side effect of taking Lipitor and warfarin together.
The provided label adverse reaction excerpts list other common adverse reactions (e.g., myalgia, diarrhea, nausea, enzyme increases) and do not describe bleeding as most common, nor specifically in combination with warfarin.
Taking Lipitor and warfarin together may increase the risk of stroke.
While the label excerpts discuss stroke risk outcomes in certain contexts, they do not provide any warfarin coadministration relationship to stroke risk in the supplied text.
Taking Lipitor and warfarin together may increase the risk of heart failure.
The provided label excerpts mention hospitalization for CHF as an outcome indication, but do not describe increased heart failure risk due to a warfarin coadministration interaction.
Contradictions
Important Omissions
No warfarin-specific interaction information (INR/bleeding/dose adjustment) is included in the provided label excerpts; therefore any guidance implying such monitoring/adjustments is not supported by the supplied labeling text.
Importance:
High
Safety Assessment
Potential Patient Risk:
Medium
Claims imply clinically actionable monitoring and dosing changes (INR frequency, dose adjustment) based on warfarin coadministration, but the supplied label excerpts do not support warfarin-specific interaction effects, increasing risk of misinformation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Warfarin interaction, INR monitoring, bleeding as common adverse event in combination, and stroke/heart failure risk claims are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit interaction statements to what the provided label supports (e.g., CYP3A4 inhibitor-related increases in atorvastatin plasma concentrations) and avoid warfarin/INR/bleeding comparative-risk guidance unless present in the supplied labeling sections.